Microgentas develops exosome extraction reagents for point-of-care molecular diagnostics, enabling the isolation and processing of circulating free DNA and microRNAs from blood samples. Their technology facilitates high-purity and high-recovery exosome extraction, addressing the need for efficient and cost-effective liquid biopsy solutions for early cancer diagnosis.
Funding
Funding not disclosed
Founders
Product
Problem
Current methods for isolating exosomes and circulating nucleic acids from liquid biopsies are often inefficient, time-consuming, and may not provide the purity or yield required for sensitive downstream diagnostics. This can hinder early cancer detection and the development of effective liquid biopsy-based diagnostic assays.
Solution
Microgentas develops and provides exosome isolation reagents and services designed to improve the efficiency and effectiveness of liquid biopsy workflows. Their portfolio includes kits and services for exosome isolation, exosome characterization, and circulating-free DNA (cfDNA) and microRNA (miRNA) extraction. Microgentas's technology aims to deliver high-purity and high-recovery of exosomes and nucleic acids from various sample types, enabling more reliable and cost-effective liquid biopsy solutions. In addition to diagnostic applications, Microgentas offers exosome原料 for cosmetic applications and explores platelet-derived EVs for therapeutic purposes.
Target Audience
Microgentas serves clinical researchers, diagnostic assay developers, and cosmetic companies seeking efficient and reliable exosome isolation and extraction technologies.
Features
- ExoCAS-2™, ExoPAS™, and ExoFilter™ kits for exosome isolation from plasma, serum, cell culture media, and urine
- ExoTFF™ technology for high-throughput exosome isolation
- miRQuick™ reagent for miRNA extraction from exosomes
- PiBEX™ kits for cfDNA extraction
- EV isolation and characterization services
- Development of exosomal miRNA-based biomarkers for early breast cancer diagnosis
- Plant-derived exosome原料 for cosmetics
- Technology for platelet EVs therapy